SecBot SecBot
8-K ·Filed Feb 26, 2026

PRVA

Privia Health Group, Inc.
BULLISH
Impact 8/10
Horizonweeks Processed8mo ago SEC0001759655-26-000007
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong beat on 2025 guidance and robust 2026 outlook suggest accelerating growth in Privia's value-based care model. Traders should monitor the company's ability to maintain high growth rates in attributed lives and provider count while expanding margins. The 80% free cash flow conversion target in 2026 could support potential share buybacks or strategic acquisitions.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$24.91
T+0 close · Feb 26, 2026 · via day close
Latest settled
−9.11%
T+60 · $22.64
Vs SPY
−16.86%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $24.91entry
  2. T+1 · 9mo ago −4.66%α −4.20% · $23.75
  3. T+5 · 9mo ago −4.30%α −3.17% · $23.84
  4. T+20 · 8mo ago −18.99%α −12.59% · $20.18
  5. T+60 · 6mo ago −9.11%α −16.86% · $22.64
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Privia Health reported strong full-year 2025 results with revenue of $2.12 billion (up 22.3% YoY), net income of $22.9 million (up 59.3%), and Adjusted EBITDA of $125.5 million (up 38.8%). All key metrics exceeded guidance. For 2026, the company guided for revenue of $2.35-$2.45 billion and Adjusted EBITDA of $145-$155 million, reflecting continued growth and strong cash flow generation with no debt.

Key Financial Metrics

Revenue
$2.1B
+22.3% YoY
Adj. EPS
$0.99
GAAP: $0.18
Guidance
$2.35B-$2.45B
raised
Free Cash Flow
$163.4M
Gross Margin
21.34%

Key Facts

  • Full-year 2025 revenue was $2.12 billion, up 22.3% YoY from $1.74 billion in 2024
  • Full-year 2025 net income was $22.9 million, up 59.3% YoY from $14.4 million in 2024
  • Full-year 2025 Adjusted EBITDA was $125.5 million, up 38.8% YoY from $90.5 million in 2024
  • All 2025 operating and financial metrics were at or above the high end of guidance
  • 2026 guidance: revenue of $2.35-$2.45 billion (10.7%-15.4% growth), Adjusted EBITDA of $145-$155 million (15.5%-23.5% growth)
  • Company ended 2025 with $479.7 million in cash and no debt

Financial Impact

Revenue increased by $386.4 million, net income by $8.5 million, and Adjusted EBITDA by $35 million year-over-year

revenueepsebitdacashFlow

Segment Breakdown

SegmentRevenueGrowth
Implemented Providers$5.4K+12.3%
Attributed Lives$1.5M+22.7%

Risk Factors

  • Forward-looking guidance is not reconciled to GAAP measures, creating uncertainty around profitability
  • Heavy reliance on value-based risk arrangements in the challenging Medicare Advantage market
  • Potential for decreased reimbursement rates from government and private payers

Market Snapshot

Exchange
Nasdaq

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001759655-26-000007
Document: prva-20260226.htm0001759655-26-000007
Document: 0001759655-26-000007-index-headers.html0001759655-26-000007
Document: 0001759655-26-000007-index.html0001759655-26-000007
Document: 0001759655-26-000007.txt0001759655-26-000007
CONTEXT: Previous Earnings (2026-02-26)0001759655-26-000007

Track record

20 reports on PRVA

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +10.73% at T+60 after the Mar 9, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Mixed 6/10 No price data
  2. Nov 5, 202611d ago Press Release Bearish 5/10 Entry $23.94 to $23.67 Now $25.26 −5.51% ▲ +1.13% +4.42% vs SPY
  3. Nov 2, 202614d ago Press Release Neutral 3/10 Entry $21.28 to $24.54 Now $25.26 +18.70% ▲ +15.32% +15.24% vs SPY
  4. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $21.48 to $24.42 Now $25.26 +17.60% ▲ +13.69% +16.39% vs SPY
  5. Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $20.30 to $21.67 Now $25.26 +24.43% ▲ +6.75% +7.73% vs SPY
  6. Jul 13, 202618w ago Insider Cluster Neutral 3/10 Entry $28.03 to $26.26 Now $25.26 −9.88% ▼ −6.31% −5.02% vs SPY
  7. Jul 9, 202618w ago Insider Cluster Neutral 3/10 Entry $27.49 to $26.90 Now $25.26 −8.11% ▼ −2.15% −0.60% vs SPY
  8. Jul 7, 202618w ago Insider Cluster Neutral 3/10 Entry $27.21 to $28.10 Now $25.26 −7.17% ▲ +3.27% +2.01% vs SPY
  9. Jul 7, 202618w ago Press Release Neutral 1/10 Entry $27.23 to $28.03 Now $25.26 −7.23% ▲ +2.94% +2.39% vs SPY
  10. Jul 2, 202619w ago Insider Cluster Neutral 3/10 Entry $27.36 to $27.77 Now $25.26 −7.68% ▲ +1.50% +0.57% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 7h 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 26, 2026